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Abstract:

Every cell contains the same genetic code, to have cell differentiation this genetic code needs to
be regulated on what is expressed. The regulation ofgene expression without altering the genetic
code itself is known as epigenetics. An example ofepigenetic regulation can be seen between the
binding ofUHRF2 and H3 histones. The purpose ofthis project is to determine ifD363 in
UHRF2 is important for histone H3 binding. To do so, D363 was mutated to alanine, lysine or
asparagine. The mutant protein was expressed, purified, and its ability to binding to H3 was
tested by fluorescence polarization. Compared to wildtype UHRF2 PHD which bound histone
H3, the D363A, D363K and D363N mutants showed no binding. This suggests D363 is critical
for the UHRF2: H3 interaction.
Introduction:

Cancer is a growing problem throughout the world, it is estimated that nearly one out ofthree
Americans will be diagnosed with cancer throughout their lifetime. This means that in 2018 an
estimated 1,735,350 newly cases of cancer will be diagnosed, and 609,640 Americans will die of
cancer 1• While cancer is not the leading cause ofdeath in the United States, it is second, coming
in behind heart disease2• Common treatments for cancer include chemotherapy, surgery,
radiation therapy, and immunotherapy, with a large push for preventative action also playing a
role in fighting cancer 1• However, most ofthese treatments are harsh on the body and remission
is not guaranteed. As such new approaches to cancer treatments are constantly researched and
new drugs developed to try and better every patients' odds.
One such approach is by using the field ofepigenetics. Epigenetics is the alteration to gene
and/or protein expression without altering the DNA sequencing itself3. By controlling what

..
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genes are being expressed, epigenetics can be used to fight cancer by slowing cancer growth and
thus allow for less treatment needed to become cancer free. Eukaryotic DNA is organized into
higher order structures called nucleosomes. Nucleosomes are composed of approximately 150
DNA base pairs coiled around an octamer of histone proteins, with each octamer containing 2
sets of the 4 histone proteins H2A, H2B, H3, and H4 and packaged as chromatin Modifications
on the tails of histone proteins are epigenetic markers that function to regulate gene expression.
This can happen through the addition of small molecules to proteins/DNA, such as the addition
of a methyl, acetyl, or phosphoryl group, or by the binding of proteins known as reader proteins
to the histones4• Within cancer cells, certain proteins are up regulated to cause gene expression
that encodes for cell growth. One such protein that does this and is often overexpressed in cancer
isUbiquitin-like containing plant Homeodomain and Ring finger 1 orUHRFl 5•UHRF 1 has
been extensively studied and the crystalized protein complex ofUHRFl bound to the HJ histone
has already been determined6•
However, a genetically similar reader protein toUHRFI is Ubiquitin-like containing plant
Homeodomain and Ring finger 2 calledUHRF2 for short7.UnlikeUHRFl,UHRF2 has not
been extensively studied and while a crystalized structure ofjust UHRF2 is available, a
crystalized structure ofUHRF2 in complex with H3 is not available. WhileUHRFI is commonly
overexpressed in cancers,UHRF2 is both overexpressed as well as repressed in cancers7.This
meansUHRF2 is capable of being both an oncoprotein and a tumor suppressor protein. An
oncoprotein causes a cell to be transformed into a cancerous one; while a tumor suppressor
protein prevents this transformation or suppresses the proliferation of cancerous cells if
transformation does occur5. One function ofUHRF2 is that it recruits transcription proteins for
expressing genes that tum off growth genes7• Within bothUHRFI andUHRF2 are the same two
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histone binding domains that have 40-60% similarity in genetic sequencing, these domains are
called Tandem-Tudor Domain (TTD) and a Plant Homeo Domain (PHO), as shown in figure l
89
• •

UHRFl has been shown to interact with multiple recognition sites on histone H3 through the

TTO and PHO domains. The similarities betweenUHRF2 andUHRFl suggest that similar
binding mechanisms exist inUHRF2 10•Using an overlay ofH3 boundUHRFl crystal with
unboundUHRF2 (figure 1 ), sites ofUHRF2:H3 binding within the TTD and PHO domain can
be predicted and tested.

Structures of TTD-PHD of
UHRF1 and 1.l,JRF2

TTD

PHD

Figure 1: Overlapping crystal structures of UHRFl TTD-PHD·H3K9me36 and UHRF2 TTD-PHD lmked domainll.

As shown in figure 1,UHRFl andUHRF2 TTD domains overlay very well, while the PHO
domains do not. This is likely being caused by the flexibility of the linker domain between the
two proteins and not due to the domains not being similar. This can further be shown to be true
by figure 2 which shows the overlay of the two PHD domains.
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The binding between H3 and UHRFl PHD domain is known to be done by two charge
interactions between Arginine residue in the H3 and Aspartic Acid residue in the PHO domain4•
By comparing the overlay ofUHRFl in complex with H3 with UHRF2, the Aspartic Acid in
position 363 was found to be close to one of the Arginine residues in H3. As binding between
these two residues was already shown in UHRFl, it is hypothesized that 0363 in UHRF2 was a
point of binding between the UHRF2 PHO domain and the H3.
The focus of this specific research project is to interrogate the H3 binding interactions within the
single UHRF2 domain PHO. This is tested by removing the Aspartic Acid and replacing it with
three other residues. By characterizing the 0363 binding site of UHRF2 to histone H3, an
anticancer drug can eventually be developed to inhibit UHRF2 by disrupting histone interactions.

Figure 2: (Left) UHRFl (blue) in complex with H36 (orange} with UHRf21l (green) overlaid to show likely points of binding. {Right)
A zoomed in section of H3 with UHRFl and UHRF2 with the Arginine and Aspartic Acid residues believed to be binding shown
inside the red square.

Experimental Procedure:

Plasmid: The mutations were performed on the pGEX-KG UHRF2 PHO plasmid. This small,
double stranded, circular piece of DNA contains multiple segments that are used throughout the
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experimental process. The first is an origin of replication where the plasmid begins the process of
DNA replication. Next is a lac repressor gene that codes for a protein that prevents the
expression of the proteins encoded within the plasmid. Then, there is a tac promoter region that
drives high expression of downstream genes. After this is a gene that codes for glutathione s
transferase (GST-n enzyme tag). Downstream is the gene that codes for theUHRF2 PHO
domains. In the final protein product, the GST is at the N tenninal end of and covalently
attached to the expressedUHRF2 PHO. The GST tag is useful for its purification and also plays
a helpful role in the expression, folding, and solubility of the protein l 0, 1 1. Finally, the last gene
is one that codes for the enzyme P-lactamase. This enzyme provides cells that take up this
plasmid with resistance to the antibiotic ampicillin.
Primers: The mutation in the pGEX-KGUHRF2 PHO plasmid was added using forward and
reverse primers. These short pieces of single stranded DNA each introduce the mutation into one
of the strands of the double stranded plasmid. They serve as a starting point for DNA replication
by DNA polymerase with the mutation already incorporated. The primers were designed and
ordered for creation by Dr. Albaugh.
Cite Directed Mutagenesis Using Inverse PCR: An inverse polymerase chain reaction (PCR) was
performed to create and then amplify the mutated version ofUHRF2 PHO. To prevent
contamination from foreign DNA from being amplified in the sample, reagents were assembled
in biosafety hood. 10 ng of pGEX-KGUHRF2 PHO template DNA, 200 nM of forward and
reverse primers, 25 uL Clone Amp Hifi PCR Premix, and 22 uL nuclease free water were
combined in a PCR tube. The PCR premix contains buffer, salts, metals, water, dNTPs
(deoxynucleotide triphosphates, or bases), and DNA polymerase. The tube was then placed in a
thennocycler with two other empty PCR tubes to prevent melting of the tube of interest. The
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thermocycler first heats the sample to 98 C for 1 0 seconds to break the hydrogen bonds between
the strands of the pGEX-KGUHRF2 PHD plasmid DNA, this separates the strands. The
thermocycler then switches to 55 C for 10 seconds which allows the primers to bind to the
complementary sequenced bases on the separated strands. The temperature is then raised to 72 C
for 30 seconds in which DNA polymerase synthesizes DNA using the plasmid as a template. The
three temperature stages are then cycled to amplify mutant DNA. Inverse PCR was performed in
which the primers anneal and amplify DNA in opposite directions to amplify the entire template
rather than standard PCR in which the primers face one another and amplify only a portion of the
template. The resultant mutant DNA is linear which allows for only the circular DNA template to
be degraded during DPNl Digest.
DPNl Digest: 40 uL of nuclease free water, IO uL of CutSmart buffer, 48 uL of PCR product,
and 2 uL of the DPNl enzyme were combined in a microfuge tube and centrifuged at 13000 rpm
for one minute. The tube was then placed in a 37 C water bath for 1 hour to allow the enzyme to
cleave the methylated DNA at its optimal temperature. Following this, the tubes were heated at
80 C for 20 minutes to denature the enzyme and stop its function.
Plasmid Transformation into Rosetta DE3 cells: 20µ1 of Rosetta DE3 competent cells were
added to pre-chilled microfuge tubes on ice followed by either I µI of DNA or no DNA (negative
control tube), gently mixed the tubes and incubated on ice for 15 minutes. The cell/DNA
mixtures were heat shocked in a 42°C water bath for 30 seconds and then returned to ice for 2
minutes. 250 µI of Super Optimal Broth (SOB) was to each tube and placed in 37°C rotating
incubator for 40 minutes. The whole sample was spread on the prewarrned LB-Agar-Ampicillan
Choramphenicol plates and placed back in a 37 incubator for overnight growth.
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DNA Purification: Colonies from the overnight transformation plates is grown in SOB overnight.
Colonies selected were uniform in appearance and were not touching other colonies. These cells
are pelleted at top speed for 1 minute in two 1.5ml portions, the supernatant was decanted each
time. Pellets were resuspended in 250 µl ofCell resuspension solution and 250 µl ofcell lysis
solution was added. The solution was gently inverted three times and 10 µl ofAlkaline Protease
solution was added and incubated for 5 minutes. 350 µl ofneutralization solution was added and
the tubes were centrifuged at top speed for 10 minutes. The resulting supernatant was then added
to spin columns attached to a vacuum adaptor and pulled through with a vacuum. 750 µl ofwash
solution was vacuumed through followed by a second wash of250 µI. After the washes the
samples were left on the vacuum running for 10 minutes. The columns were transferred into new
microfuge tubes and centrifuged at top speeds for 2 minutes. To free the DNA from the column,
I 00 µl ofnuclease free water was added to the columns and spun again at top speed for 1 minute.
Nanodrop Spectrophotometric Analysis ofDNA Samples: Nanodrop spectrophotometry was
performed to determine the purity and concentration ofDNA samples. DNA absorbs at a
wavelength around 260 nm, protein at 280 nm, and salts and buffers at 230 nm. The
concentration value is given, and purity can be determined by the 260/280 and 260/230 values.
The 260/280 value describes how much protein is in the sample with a value above 1.8
corresponding to low protein levels. The 260/230 value describes how much salt and buffer
contamination is contained in the sample with a value around 1.8-2 being ideal.
DNA Gel Run: 50ml ofAgarose DNA gel was made by mixing together 50ml of0.5X TBE and
0.35g agarose to a 250ml flask and left to settle for at least two minutes. The flask opening was
covered with plastic wrap and a small whole pierced in the plastic wrap for ventilation. The flask
was microwaved until bubbles begin to appear in the solution (about 1 minute). The flask was
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removed and stirred before returning to microwave for an additional minute. The solution was
cooled for 2-4 minutes and then 1 µl ofGel Red Staining Reagent added. The gel casting tray
was set up and made sure that it is properly sealed and the correctly sized comb for the number
ofwells needed added before pouring in the gel. The gel to cooled for at least 30 minutes
For the DNA samples, a total of 12 µI volumes was prepared:2 µl ofthe DNA, ladder, or water
for the negative controls, 2 µl ofpurple loading dye, and 8 µI ofnuclease free water. To each
well, only 10 µl were added. The gel was then ran at 120V for up to a total of45 minutes and
checked every 15 minutes to insure the samples did not run off the gel.
Protein Expression: One colony from a transformation plate was inoculated into 50ml LB growth
media containing 50 µl of I000X Ampicillin and 50µ1 of I 000X Chloramphenicol in a sterile
environment and left to incubate in the rotating incubator at 37°C overnight. 10ml ofthis
overnight solution was added to a 1L container ofLB growth media along with 1 ml of 1000X
Ampicillin and 1000X Chloramphenicol and incubated in rotating incubator for two hours at
37°C. After 2 hours the absorbance was measured. As a rule ofthumb for this bacterium, cell
growth doubles every 30 minutes. The absorbance was checked every 30 minutes and removed
from incubator when OD600 was between 0.4-0.5. 1ml IPTG was to the IL sample and the
temperature lowered to 2 l 0C and shaken in the incubator overnight. The centrifuge, a Sorvall RC
SB Plus with a Sorvall SLA-3000 Super-Lite fixed angle rotor, was used to pellet the cells for 10
minutes at 5000rpm and supernatant decanted. The pellet was then frozen in a 50ml conical and
placed in the -20°C freezer.
Protein Purification: Frozen pelleted cells from protein expression were placed on ice to thaw.
3.5 µl BME was added to 50ml ofTriton Lysis Buffer II (0.5% Triton, 10% glycerol, 150 mM
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NaCl, and 50 mM Tris, 1 mM 2-Mercaptoethanol (BME)). From this solution, 1 0ml of 1 0mg/ml
Lysozyme in Triton Lysis Buffer II was made. 27ml of Triton Lysis Buffer II and 3ml of
Lysozyme in Triton Lysis Buffer II was added to the thawed cell pellet. PMSF at a stock
concentration of 1 00 mM, leupeptin at a stock concentration of 1 0 mg/mL, and aprotinin at a
stock concentration of 5 mg/mL were added to a final concentration of 1x to the thawed cell
pellet and mixed until the mixture is homogenous. If the solution did not become homogenous
after 10 minutes, up to an additional 3ml of the Lysozyme in Triton Lysis Buffer II solution was
added in 1 ml increments with 3-5 minutes of stirring to see if homogenous before another I ml
was added. 30 µl ofONAsel was added to the tube and stirred on ice for 1 0-15 minutes. This
should leave the solution as homogenous and with the consistency of water, if it is not, more
ONAse 1 was added and stirred at room temperature for 10-15 minutes. I 00 µl of sample was
collected and stored in test tube labeled all of cell for SOS gel run. The sample was then
centrifuged for 30 minutes at 1 3000 rpm. A portion of the pellet and the supernatant was
collected and placed into labeled tubes for the SOS gel run. The supernatant was ran on a OST
tagged column in the cold room through tubing with gravity pulling the supernatant through at a
rate around 0.5ml per minute, the liquid removed from the column is collected and known as the
flow through. Between the flow through and elution the column is washed with around 1 00ml of
Triton Lysis Buffer II to remove all unbound proteins from the column. The eluent was collected
at a rate around 0.25ml per minute to allow the resin beads to release the boundUHRF2 protein
in favor for the elute buffer of 1 0 mL of 50 mM Tris, pH 8.0, 10 mM reduced glutathione. The
eluent was collected and placed in Thermo Fisher Scientific 10,000 MWCO (molecular weight
cut oft) snakeskin dialysis tubing and dialyzed overnight in 1 L of 10% glycerol, 50 mM Tris,
1 50 mM NaCl, 1 mM BME dialysis buffer at a pH of 7.5 with stirring. The next day, the solution
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was centrifuged in Coming Spin-XUF 30,000 MWCO concentrator tubes in an Allegra 25R
centrifuge in a Beckman Coulter TA-10-250 fixed-angle aluminum rotor at 6000 ref and 4 C
until concentrated to around l mL. The l mL was then aliquoted as 1 00 µI into 1 .7ml microfuge
tubes. To prevent protein degradation, the microfuge tubes were snap frozen in liquid nitrogen
and stored in -80 C freezer.
DC Assay:
From 25mg/ml BSA, 2.5mg/ml BSA was made with water. Six tubes were set up with the
following concentrations.
Table 1: Concentration table for BSA tubes

µg BSA

µ1 2.5 BSA

µI water

0

0

25

5

2

23

IO

4

21

15

6

19

20

8

17

25

IO

15

The protein was diluted to 1 /5 by adding 20µ1 of protein to 80µ1 of water. Three test tubes were
prepared with varying concentrations of protein 1 /5.
Tobie 2: Concentration table from 1/5 protein concentration

µI of 1/5 protein

µI water

5

20

IO

15

15

IO
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First, 2ml reagent A and to 40 µI reagent S was prepared in 15ml tube and mixed to vortex.
150µ1 ofthis solution was added to each ofthe nine test tubes prepared. 1ml ofreagent B was
added to each ofthe nine test tubes, vortexed and incubated for 15 minutes at room temperature.
Nine cuvettes were labeled and 1ml ofeach sample was added to the matching cuvettes. The
Spectrophotometer was used to read samples at 750nm. A Beckman Coulter DU 800 UVNis
Spectrophotometer was used to read samples at 750nm. The BSA results were graphed and a
standard curve (Fig. 3) was created. As Beer's Law (Fig. 4) shows, there is a direct relationship
between absorbance and concentration. Thus, the BSA standard curve can be used to calculate
the protein concentration from the absorbance readings ofthe 1/5 protein concentration samples
using the linear trendline, by plugging the absorbance in for x and solving for y.

Standard Curve

--· ---�---1-- r. . . •· ·• --

30
25

+

20
� 15

�•

:;; 10
5
0
-5

••. •
0

·
···· ·

·
•• •· ···• ·

0.05

· ······
·
...•· · ····•······� · ·····:·�
··· ·

0.1

y = 75.406x-0.7124

0.15

f I

0.2

0.25

•···· ·
·

- ....., ______
0.3

0.35

0.4

Absorbance

Figure 3: Example graph of BSA µg protein against Absorbance with a trendline fit to it showing the linear relationship

A= ebc
Figure 4: Beer's Law equation

Fluorescence Polarization:
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A Fluorescence Polarization Buffer was prepared by combining 50ml of 50mM Tris with a pH of
7.5 with 0.05g ofBSA. This solution was then filter sterilized using a sterile syringe filter with a
0.2µm Polyethersulfone Membrane and a 60ml sterile syringe. To the sterilized Fluorescence
Polarization Buffer 50µ1 of 1000x stock protease inhibitors were added: Aproptinin, Luepeptin,
and PMSF. When the buffer was not in use it was kept on ice. H3 peptides had covalently
attached to the C terminus a 5 carboxyfluorescein (5-FAM) fluorophore molecule that is capable
offluorescing. When light of a wavelength of485 nm is shone on the tluorescein, it excites the
electrons within it from the ground energy state, or unexcited state, to an excited electron energy
state. This light is then emitted at a different wavelength, 528 nm, as the electron returns to
ground state after a set amount of time. Preparation ofthe Histone H3 peptides differed due to
concentrations when unmodified or modified H3 was used. Thus, using nuclease free water, the
peptide concentrations were made to be 100nmol per 1000ml.This was done to a total volume of
1ml in a 1.7ml microcentrifuge tube and kept on ice. To protect the fluorescing peptide, the
amount ofexposure to light should be kept to a minimum as well and was done so by wrapping
H3 peptide containers in aluminum foil. To perform the FP assay, four replicates of 11 binding
reactions were performed containing the Fluorescence Polarization Buffer with PMSF, leupeptin,
and aprotinin protease inhibitors added to it, 10 nM ofthe H3K9me3-fluorescein peptide, and
varying concentrations ofthe mutant UHRF2 PHO. To do so, a black, opaque, 96 well plate was
prepared. The 96 well plate had a serial dilution done in row A starting with 100% protein
solution in column 12 and then being diluted by mixing with the Fluorescence Polarization
Buffer from columns 11 through 3 and no protein is added to column 2. In column 1 the I 00nM
ofH3 peptide is added to B, C, D, and E. From row A the column dilutions of protein are pulled
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down in l OµI amounts, and the H3 peptide in column I is pulled across the columns in 1 OµI
amounts as shown in table 3 which has the assumed protein concentration of 1 OOµM.
Table 3: Table showing example FP Assay 96 well plate provided by Zeineb EIMohri.
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Graph Creation and Kd Calculation:
Using the concentrations of protein along with the intensities of parallel to perpendicular light
from the Fluorescence Polarization Assays, a graph was created. This graphed data was then
normalized and set to the equation seen in figure 3 using the computer program Prism to
calculate a Kd value.
Percent Bound =

u

""'*

,n,cnn..,.,

EMl'TY

l'roltrin and

'

I

[protein]
. x 100
Kd + [protein]

Figure 5: Prism equation used to create a best fit curve for Fluorescence Polarization Assay Data.

Results and Discussion:
Inverse PCR was performed on 50 ul samples to create and amplify mutant pGEX-KG UHRF2
PHD DNA. Once finished, a 2 ul sample of each reaction was run, along with negative controls
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where nuclease free water was used, on a 0.7% agarose gel at 120 V for 45 minutes alongside a I
KB ladder. The resultant gel was imaged, and the bands were compared to the I KB DNA ladder
(Fig. 6) to determine success ofthe PCR reaction.
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Figure 6: Gel from electrophoresis showing if PCR was successful.

The gel shows a single dark band in the lanes that had DNA and this signifies that the replication
ofDNA was successful; the smaller and lighter bands at the bottom ofthe gel are likely primers
that bound to each other and should have no effect. With no bands ofsignificance in the negative
control lanes, contamination can be ruled out and the mutant DNA inverse PCR was successful.
After DNA gel electrophoresis, the mutants underwent a DPNI digest to remove the methylated
template DNA from the samples. The samples were then purified using PCR column purification
and transformed into Stellar Competent E. coli cells. The Stellar Competent E. coli cells mass
produced the plasmid while dividing and colony forming units were selected for plasmid
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purification. Afterwards, Nanodrop spectrophotometry was used to determine sample
concentration and purity. The values collected are seen in Table 4.
Table 4: Nanodrop results showing concentration and purification of DNA mutants.

Mutant

D363A

D363N

D363K

Concentration

260/280 Purity

260/230 Purity

1.) 97.1 ng/ul

1.89

2.72

2.) 76.9 ng/ul

1.90

3.1 1

3.) 37.4 ng/ul

1.83

-34.13

4.) 102.3 ng/ul

1.94

2.64

5.) 58.1 ng/ul

1.91

7.08

6.) 140.7

1.89

3.03

1.) 54.2 ng/ul

1 .78

0.98

2.) 96.4 ng/ul

1.66

0.77

3.) 98.l ng/ul

1.91

1.76

4.) 98.9 ng/ul

1.92

1.76

1.) 161.7 ng/ul

1.95

1.52

2.) 191.5 ng/ul

1.78

1.04

3.) 95.7 ng/ul

1.92

1.70

4.) 161.3 ng/ul

1.85

1.37

The samples were sent to theUniversity of Michigan to be sequenced by Sanger Sequencing and
for O363A samples 2,4, and 6 were correct; for D363N 1,2, and 3 were correct and D363K had
1,2, and 4 with correct sequencing.
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The mutant DNA was then transformed into Rosetta E. coli cells and left to grow overnight. The
overnight E. Coli culture was then used to inoculate a I-liter LB culture and protein induction
was performed using IPTG once the cell density absorbance value reached approximately 0.4.
The protein was then extracted from the cells and purified by OST affinity chromatography.
Once a purified sample was obtainedt SOS-PAGE was conducted to determine protein purity and
ifthe protein purification process was successful. This process was done for each mutant protein
produced as well as the Wildtype protein. The results for these four purifications are seen in
figures 7 through 10.
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Figure 7: Protein Purification of UHRF2 WT checked by SDS-Gel for successful purification.
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Figure 8: Protein Purification of D353A checked by SDS-Gel for success.
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Figure 9: Protein Purification of D353K checked by SDS-Gel for success.
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Figure 9: Protein Purification of D363N checked by SDS•Gel for success.

The samples were ran on the SOS-PAGE gels to check if protein purification was successful.
The amount of other protein in the purified protein column is negligible compared to the amount
of UHRF2 protein present. The method can be improved as seen by the presence of UHRF2
protein in the Flow through and Resin columns meaning that desired protein was lost. To lessen
this, the amount of resin used should be increased and the speed of the Flow through dripping
through the column should go at a slower speed. The protein lost on the resin could also be
prevented by having the elution go at a slower pace. Lastly, figures 9 and 1 0 are missing the
pellet that sample was not collected.
The purified protein samples were then run through a DC Assay using BSA of known
concentrations to make the standard curve. Using the trendline produced (Table 5) from the
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graphs and the absorbances of the purified proteins, the concentrations were solved as seen in the
example calculation in figure 11, which is from O363A Trial I using the absorbance of the 10µ1
of protein at a protein concentration of 1/5 total protein concentration. As multiple volume
amounts were tested, the calculated concentrations in table 6 are the average of the tests that fit
within the standard curve.
Table 5: The trendline equations created for each DC Assay done.

Mutant/Trial

Standard Curve Equation

O363A Trial 1

y = 75.406x - 0.7124

O363K and O363N Trial 1

y = 74.512x - 0.3533

O363A Trial 2 and WT Trial 1

y = 101.48x - 0.5625

O363K, O363N and WT Trial 2

y = 90.363x - 0.5333

y = 75.406x - 0. 7124
y = 75.406(0.2921) - 0.7124
y = 21.3 lµg

(

21.31 u9
l mol
1000000 µmol _
)x
xSx
- 394.4 µM
l0ul
l mol
27010 g

Figure 11: Sample calculation forfinding the protein concentration of purified proteins.

Gilliam 20

Table 6: Final calculated concentrations from DC Assay

Mutant/Trial

Concentration

O363A Trial 1

389.8221 µ M

O363K Trial 1

329.2249 µ M

O363N Trial 1

169.4104 µ M

O363A Trail 2

505.047 1 µ M

WT Trial 1

614.5047 µ M

O363KTrial 2

34.9763 µ M

O363N Trial 2

80.9957 µ M

WT Trial 2

1 94.9308 µ M

The concentrations are all are of usable amounts, the low level of protein expression in the
O363N Trial 2 and O363K Trial 2 are believed to have been caused by loss of competency in the
E. coli cells used.
To determine the binding affinity between the mutants and the modified H3 with three methyl
groups on the Lysine in the ninth position (H3K9me3) peptide, FP assays were run. The
nonlinear curve ofUHRF2 Wildtype PHO binding to the H3K9me3 shown in figure 1 2 is used to
calculate the dissociation constant (Kd). In the case of the UHRF2 WT PHO binding to
H3K9me3 the Kd measured is 0.44µM. The Kds of the mutantUHRF2 PHO proteins are then
shown in figures 12 through 15.
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UHRF2 WT PHO Against H3K9me3-FI Peptide
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Figure 12: The Fluorescence Polarization Assays done an UHRF2 PHD Wildtype, a Kd of 0.44µM.
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Figure 13: The Fluorescence Polarization Assays done an UHRF2 PHD D363A, no Kd can be calculated as no binding occurs.
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UHRF2 PHO O363K Against H3K9me3-FI Peptide
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Figure 14: The Fluorescence Polarization Assays done on UHRF2 PHD D363K, no Kd can be calculated as no binding occurs.
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Figure 15: The Fluorescence Polarization Assays done on UHRF2 PHD D363N, no Kd can be calculated as no binding occurs.

The calculated Kd of the wildtype UHRF2 from using the Fluorescence Polarization Assay
matches the results found in other studies of what the expected Kd should be in the single PHO
domain (Fig. 12).. As no binding occurs with the changing of the 363 Aspartic Acid to an
Alanine (fig. 13), it can be concluded that this is an important H3 binding site in the PHO
domain. The lack of binding between the H3 and the D363K mutation (fig. 14) is expected, as
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the predicted interaction between the PHO domain and H3 is that of a charge-charge interaction.
This mutation switches the negatively charged Aspartic Acid, to a positively charged Lysine and
the predicted repulsion between the Lysine on the PHO and the Arginine on the H3 is seen with
the lack of binding. The importance of the negative charge on the PHO domain for binding to
occur is seen in figure 15, for the mutation from an Aspartic Acid to an Asparagine is a small
change in charge while the overall shape of the two are very similar. As no binding occurs it can
be concluded that both shape and charge are highly specified for binding to occur.
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